Skip to main content
Premium Trial:

Request an Annual Quote

Whitehead Team Uses Affy Chips to Probe Immune System Response

NEW YORK, Oct. 25—A new study using DNA chips to probe the activity of the immune system indicates that dendritic cells discriminate between different kinds of invading pathogens, and are involved in directing tailored immune responses. The study, to appear in the October 26 issue of Science , was led by immunologist Nir Hacohen at the Whitehead Institute for Biomedical Research at MIT.

Hacohen’s team used Affymetrix’s GeneChips to monitor the genetic activity of dendritic cells during exposure to three different types of infectious agents: an influenza virus, the E. coli  bacteria, and the fungus Candida albicans . The researchers determined that each pathogen activated a unique set of genes, which in turn generated different elements of the immune response. For example, the bacteria activated genes that attract neutrophils, but the virus did not. 

Dendritic cells are part of the early response division of the immune system, activating other arms of the immune system in response to infectious agents such as viruses and bacteria. Their function is not as well understood as other parts of the immune response. Hacohen said the microarray chips provided “a way of getting a snapshot of the state of dendritic cells.” He said, “By looking at many genes you get a rapid assessment of what the dendritic cell is capable of doing. There’s no other way to get such a comprehensive snapshot. You could look at a gene here, or a gene there, but this is the only way to get the global view.” 

According to Hacohen, the team has identified a large set of genes that are activated in the presence of pathogens, and the next step is to determine what function theses genes have in dendritic cells and how they are turned on and off. Those insights may then be applied to design better therapies.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.